Department of Interventional Neuroradiology, CHU Lille, Lille, France.
Department of Vascular Neurology-Stroke Unit, CHU Lille, Lille, France; Inserm U1171-Degenerative and Vascular Cognitive Disorders, Lille, France.
World Neurosurg. 2021 Jul;151:e387-e394. doi: 10.1016/j.wneu.2021.04.040. Epub 2021 Apr 18.
We aimed to evaluate the safety and efficacy of endovascular thrombectomy (EVT) using the EmboTrap Revascularization Device (EmboTrap) in patients with ischemic stroke treated >6-24 hours after stroke onset.
We performed a retrospective analysis of data from a prospective registry of consecutive patients with stroke with anterior circulation large vessel occlusion treated by stent-retriever thrombectomy with EmboTrap II in a single stroke center in France from 2016 to 2017. Patients were divided into late treatment window (>6-24 hours after stroke onset) or early treatment window (≤6 hours) groups. Baseline clinical and imaging characteristics, rates of successful recanalization (modified Thrombolysis in Cerebral Infarction score ≥2b), complications, 3 months good functional outcome (modified Rankin Scale score 0-2), and mortality were analyzed.
Of the 225 patients (mean age, 71.5 ± 14.5 years; 55.6% [125/225] female) included in the study, 54 were treated in the late treatment window, with a mean time from last known well to treatment of 651 ± 223 minutes. Compared with the early treatment window group, there were no significant differences in baseline characteristics, successful recanalization (83.3% [45/54] vs. 81.3% [139/171]; P = 0.734), 3 months good functional outcome (37.0% [20/54] vs. 37.4% [64/171]; P = 0.959), or mortality (24.1% [13/54] vs. 27.5% [47/171]; P = 0.621).
This real-world study provides evidence that EVT using EmboTrap is safe and effective in the late treatment window in patients with large vessel occlusion.
我们旨在评估血管内血栓切除术(EVT)使用 EmboTrap 再通装置(EmboTrap)在缺血性卒中患者中的安全性和疗效,这些患者在卒中发作后 6-24 小时以上接受治疗。
我们对 2016 年至 2017 年期间法国一家卒中中心连续接受支架取栓术联合 EmboTrap II 治疗的前循环大血管闭塞性卒中患者的前瞻性登记研究数据进行了回顾性分析。患者被分为晚期治疗窗口(卒中发作后 6-24 小时)或早期治疗窗口(≤6 小时)组。分析了基线临床和影像学特征、再通率(改良脑梗死溶栓评分≥2b)、并发症、3 个月时良好的功能结局(改良 Rankin 量表评分 0-2)和死亡率。
在纳入的 225 例患者(平均年龄 71.5±14.5 岁;55.6%[125/225]为女性)中,54 例在晚期治疗窗口接受治疗,从最后一次认知正常到治疗的平均时间为 651±223 分钟。与早期治疗窗口组相比,两组基线特征、再通率(83.3%[45/54]与 81.3%[139/171];P=0.734)、3 个月时良好的功能结局(37.0%[20/54]与 37.4%[64/171];P=0.959)或死亡率(24.1%[13/54]与 27.5%[47/171];P=0.621)无显著差异。
这项真实世界研究提供了证据,表明在大血管闭塞患者中,晚期治疗窗口使用 EmboTrap 的 EVT 是安全有效的。